Brief: Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™
29/01/2026 21:02
Denali Therapeutics Inc DNLI.O: DENALI THERAPEUTICS ANNOUNCES DATA PRESENTATIONS ON ENZYME TRANSPORTVEHICLE‚ĄĘ PROGRAMS FOR HUNTER SYNDROME, SANFILIPPO SYNDROME TYPE A AND POMPE DISEASE AT UPCOMING 2026 WORLDSYMPOSIUM‚ĄĘ DENALI THERAPEUTICS INC: FDA DECISION ON TIVIDENOFUSP ALFA BLA EXPECTED BY APRIL 5, 2026 Source text: ID:nGNX7npk2Q Further company coverage: DNLI.O
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers